Hautveränderungen bei rheumatoider Arthritis

Zusammenfassung

Ein Großteil der Patienten mit rheumatoider Arthritis entwickelt im Verlauf der Erkrankung extraartikuläre systemische Symptome, die die Morbidität erheblich beeinflussen. Da Veränderungen der Haut frühzeitig sichtbar werden, sind Hautsymptome oftmals diagnostisch wegweisend. Eine dermatologische Mitbetreuung der Patienten ist daher wünschenswert. Unsere Übersichtsarbeit beschreibt das Spektrum krankheitsspezifischer Hautveränderungen und gibt einen Überblick über ausgewählte dermatologische Erkrankungen, die durch die immunsuppressive Therapie hervorgerufen werden können.

Summary

The majority of patients with rheumatoid arthritis develop extraarticular systemic symptoms which considerably increase the morbidity of these patients. Because skin lesions may be observed at early stages they are often diagnostic. Forthisreason referralof these patients to dermatologists is warranted. Our review summarizes the spectrum of cutaneous manifestations of rheumatoid arthritis and dermatologic conditions caused by immunosuppressive therapy.

Schlüsselwörter

Rheumatoide Arthritis - Hauterkrankungen - Immunsuppression

Keywords

Rheumatoid arthritis - skin manifestations - immunosuppression

• Literatur

• 1 Ackerman AB.. Histologic diagnosis of inflammatory skin diseases: a method by pattern analysis. Philadelphia: Lea & Febiger 1978; 449: 50.
• 2 Berg D., Otley CC.. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002; 47: 1-17.
• 3 Brooklyn T., Dunnill G., Probert C.. Diagnosis and treatment of pyoderma gangrenosum. BMJ 2006; 22 333 (22) 181-184.
• 4 Brown TS., Fearneyhough PK., Burruss JB., Callen JP.. Rheumatoid neutrophilic dermatitis in a woman with seronegative rheumatoid arthritis. J Am Acad Dermatol 2001; 45: 596-600.
• 5 Burge D.. Etanercept and squamous cell carcinoma. J Am Acad Dermatol 2003; 49: 358-359.
• 6 Chakravarty EF., Genovese MC.. Associations between rheumatoid arthritis and malignancy. Rheum Dis Clin North Am 2004; 30: 271-284.
• 7 Chakravarty EF., Michaud K., Wolfe F.. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005; 32: 2130-2135.
• 8 Chen KR., Toyohara A., Suzuki A., Miyakawa S.. Clinical and histopathological spectrum of cutaneous vasculitis in rheumatoid arthritis. Br J Dermatol 2002; 147: 905-913.
• 9 Douglas KM., Ladoyanni E., Treharne GJ.. et al. Cutaneous abnormalities in rheumatoid arthritis compared with non-inflammatory rheumatic conditions. Ann Rheum Dis 2006; 65: 1341-1345.
• 10 Dykman CJ., Galens GJ., Good AE.. Linear subcutaneous bands in rheumatoid arthritis. An unusual form of rheumatoid granuloma. Ann Intern Med 1965; 63: 134-140.
• 11 Efthimiou P., Paik PK., Bielory L.. Diagnosis and management of adult onset Still&quote;s disease. Ann Rheum Dis 2006; 65: 564-572.
• 12 Espinoza LR., Espinoza CG., Vasey FB., Germain BF.. Oral methotrexate therapy for chronic rheumatoid arthritis ulcerations. J Am Acad Dermatol 1986; 15: 508-512.
• 13 Esser AC., Abril A., Fayne S., Doyle JA.. Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J Am Acad Dermatol 2004; 50 (Suppl. 05) Suppl S75-S77.
• 14 Euvard S., Kanitakis J., Claudy A.. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681-1691.
• 15 Euvard S., Kanitakis J., Claudy A.. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681-1691.
• 16 Genta MS., Genta RM., Gabay C.. Systemic rheumatoid vasculitis: a review. Semin Arthritis Rheum 2006; 36: 88-98.
• 17 Gerbing EK., Metze D., Luger TA., Stander S.. Interstitial granulomatous dermatitis without arthritis: successful therapy with hydroxychloroquine. J Dtsch Dermatol Ges 2003; 1: 137-141.
• 18 Gridley G., McLaughlin JK., Ekbom A.. et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 85: 307-311.
• 19 Hafner J., Schneider E., Burg G., Cassina P.. Management of leg ulcers in patients with rheumatoid arthritis or systemic sclerosis: the importance of concomitant arterial and venous disease. J Vasc Surg 2000; 32: 322-329.
• 20 Hata T., Kavanaugh A.. Rheumatoid arthritis in dermatology. Clin Dermatol 2006; 24: 430-437.
• 21 Jogi R., Tyring SK.. Therapy of nontuberculous mycobacterial infections. Dermatol Ther 2004; 17: 491-498.
• 22 Jorizzo JL., Daniels JC.. Dermatologic conditions in rheumatoid arthritis. J Am Acad Dermatol 1983; 8: 439-457.
• 23 Karagas MR., Cushing Jr GL., Greenberg ER.. et al. Non-melanoma skin cancers and glucocorticoid therapy. Br J Cancer 2001; 85: 683-636.
• 24 Lebwohl M., Blum R., Berkowitz E.. et al. No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. Arch Dermatol 2005; 141: 861-864.
• 25 Lee HH., Song IH., Friedrich M.. et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 2007; 156: 486-491.
• 26 Long D., Thiboutot DM., Majeski JT.. et al. Interstitial granulomatous dermatitis with arthritis. J Am Acad Dermatol 1996; 34: 957-961.
• 27 Lu CI., Yang CH., Hong HS.. A bullous neutrophilic dermatosis in a patient with severe rheumatoid arthritis and monoclonal IgA gammopathy. J Am Acad Dermatol 2004; 51 (Suppl. 02) Suppl S94-S96.
• 28 Magro CM., Crowson AN.. The spectrum of cutaneous lesions in rheumatoid arthritis: a clinical and pathological study of 43 patients. J Cutan Pathol 2003; 30: 1-10.
• 29 McRorie ER., Ruckley CV., Nuki G.. The relevance of large-vessel vascular disease and restricted ankle movement to the aetiology of leg ulceration in rheumatoid arthritis. Br J Rheumatol 1998; 37: 1295-1298.
• 30 McRorie ER.. The assessment and management of leg ulcers in rheumatoid arthritis. J Wound Care 2000; 9: 289-292.
• 31 Mellemkjaer L., Linet MS., Gridley G.. et al. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996; 32A: 1753-1757.
• 32 Reichrath J., Bens G., Bonowitz A., Tilgen W.. Treatment recommendations for pyoderma gangreno-sum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 2005; 53: 273-283.
• 33 Sangueza OP., Caudell MD., Mengesha YM.. Palisaded neutrophilic granulomatous dermatitis in rheumatoid arthritis. J Am Acad Dermatol 2002; 47: 251-257.
• 34 Sayah A., English 3rd JC.. Rheumatoid arthritis: a review of the cutaneous manifestations. J Am Acad Dermatol 2005; 53: 191-209.
• 35 Smith KJ., Skelton HG.. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor a receptor IgG1-Fx fusion complex therapy. J Am Acad Dermatol 2001; 45: 953-956.
• 36 Sorensen HT., Mellemkjaer L., Nielsen GL.. et al. Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst 2004; 96: 709-711.
• 37 Thomas E., Bruster DH., Black RJ., Macfarlane G.. Risk of malignancy among patients with rheumatic condition. Int J Cancer 2000; 88: 497-502. Thurtle OA, Cawley MID. The frequency of leg ulceration in rheumatoid arthritis: a survey.J Rheumatol 1983; 10: 507–509.
• 38 Turesson C., Jacobsson L., Bergström U.. Extraarticular rheumatoid arthritis: prevalence and mortality. Rheumatology 1999; 38: 668-674.
• 39 Wolfe F., Michaud K.. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18.572 patients. Arthritis Rheum 2004; 50: 1740-1751.
• 40 Wolfe F., Michaud K., Chakravarty EF.. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology 2006; 45: 1370-1375.